The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Camostat mesilate (Primary)
- Indications COVID 2019 infections; Severe acute respiratory syndrome
- Focus Therapeutic Use
- Acronyms CamoCO-19
Most Recent Events
- 18 Apr 2025 Status changed from recruiting to completed.
- 05 Oct 2021 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.
- 27 Apr 2021 Status changed from active, no longer recruiting to recruiting.